Brain-derived neurotrophic factor (BDNF) plays a regulatory role in neuronal differentiation and synaptic plasticity and has been linked to glucose regulation and cognition. Associations among plasma BDNF, cognition, and insulin function were explored. Forty-one participants with impaired insulin function (IIF), ranging from insulin resistance to type 2 diabetes mellitus (T2DM), were matched with 41 healthy controls on gender, age, education, and IQ. Participants received complete medical, neurological, psychiatric, and neuropsychological evaluations. IIF individuals had significantly lower plasma BDNF levels than controls, particularly females, and higher BDNF levels were associated with poorer explicit memory in IIF females, suggesting that higher levels within this group may reflect the body's efforts to respond to damage. After accounting for age, education, and HbA1c, BDNF significantly predicted 13.1-23.5% of the variance in explicit memory in IIF women. These findings suggest that BDNF elevations within diseased groups may not always be a marker of health.
Introduction
Brain-derived neurotrophic factor (BDNF) is a neuronal growth factor that plays a regulatory role in neuronal differentiation, synaptic plasticity, and apoptosis (Chiaramello et al., 2007; Lang, Hellweg, Seifert, Schubert, & Gallinat, 2007; Szatmari, Kalita, Kharebava, & Hetman, 2007) . BDNF is found in high concentrations in the central nervous system (CNS) and the periphery, where it is stored in platelets and released into plasma (Fujimura et al., 2002) . Peripheral BDNF crosses the blood brain barrier by a high-capacity saturable transport system (Pan, Banks, Fasold, Bluth, & Kastin, 1998) . BDNF levels in CSF reportedly parallel those measured in plasma during brain development (Karege, Schwald, & Cisse, 2002) , suggesting that peripheral BDNF levels reflect BDNF levels in the CNS.
BDNF has been associated with metabolic processes and disease states. Elevations have been linked to exercise in both animals and humans (Berchtold, Chinn, Chou, Kesslak, & Cotman, 2005; Rojas Vega et al., 2006; Soya et al., 2007) , while reductions have been implicated in Alzheimer's disease (Laske et al., 2006 ), Huntington's disease (Ciammola et al., 2007) , schizophrenia (Gama et al., 2007) , and depression (Piccinni et al., 2008) .
BDNF affects glucose metabolism and possibly insulin sensitivity. BDNF reduces serum glucose, insulin, and HbA1c levels when injected into diabetic rats, possibly improving insulin sensitivity (Tonra et al., 1999) . However, there are inconsistent findings on BDNF and glucose metabolism interactions in humans: individuals with T2DM had decreased plasma BDNF, independent of obesity (Krabbe et al., 2006) , while others reported increased serum BDNF in T2DM, associated with obesity (Suwa et al., 2006) . Some physiological characteristics and medications may affect BDNF levels, although evidence is again inconsistent. In non-T2DM patients, body mass index (BMI) was negatively associated with plasma BDNF (Lommatzsch et al., 2005) , yet it has also been positively correlated with plasma and serum BDNF (Suwa et al., 2006) . Additionally, cholesterol lowering drugs (statins) reportedly increase BDNF levels (Chen, Zhang et al., 2005; Wu et al., 2008) .
Finally, gender may impact BDNF levels. Women were found to have higher plasma and whole-blood BDNF than men, which may be affected by body weight (Lommatzsch et al., 2005; Trajkovska et al., 2007) . This parallels well-established gender differences in vascular health biomarkers that are related to cognition such as HDL and C-reactive protein (Klimis, Gnardellis, & Trichopoulou, 2000; Lakoski et al., 2006; Seidell et al., 1991; Siqueira et al., 2008) .
There is good evidence that insulin sensitivity and BDNF may affect cognition and neural integrity in both animals and humans.
